Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a medical-device company focused on cardiovascular therapies, including its BackBeat CNT cardiac neuromodulation platform for hypertension management and the Virtue sirolimus-eluting angioplasty balloon for coronary artery disease. The company went public through a SPAC merger and filed a 10-Q with the SEC on November 14, 2022, accession number 0001213900-22-072388, reflecting its status as a reporting public company in the medical devices and healthcare technology sector. OBIO operates at the intersection of device innovation and neuromodulation science, with its lead programs advancing through clinical-stage development. Sign up at SpacDesk for full filing history, deal terms, and real-time data on OBIO and hundreds of other SPAC-origin companies.